1. Home
  2. JFIN vs EDIT Comparison

JFIN vs EDIT Comparison

Compare JFIN & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JFIN

Jiayin Group Inc.

HOLD

Current Price

$4.70

Market Cap

223.6M

Sector

Finance

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$3.35

Market Cap

206.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFIN
EDIT
Founded
2011
2013
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
223.6M
206.0M
IPO Year
2018
2016

Fundamental Metrics

Financial Performance
Metric
JFIN
EDIT
Price
$4.70
$3.35
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$4.92
AVG Volume (30 Days)
85.2K
1.5M
Earning Date
06-03-2026
05-11-2026
Dividend Yield
17.70%
N/A
EPS Growth
N/A
37.50
EPS
N/A
N/A
Revenue
N/A
$31,937,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.35
N/A
Revenue Growth
N/A
132.64
52 Week Low
$3.70
$1.23
52 Week High
$18.70
$4.54

Technical Indicators

Market Signals
Indicator
JFIN
EDIT
Relative Strength Index (RSI) 43.95 76.81
Support Level $3.70 $3.32
Resistance Level $7.22 $3.58
Average True Range (ATR) 0.30 0.22
MACD 0.07 0.08
Stochastic Oscillator 75.38 83.74

Price Performance

Historical Comparison
JFIN
EDIT

About JFIN Jiayin Group Inc.

Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: